Open AccessFibrin Clots Maintain the Viability and Proliferative Capacity of Human Mesenchymal Stem Cells: An In Vitro Study
Author(s) -
Ryan J. Warth,
Paul G. Shupe,
Xueqin Gao,
Mohammad Syed,
Walter R. Lowe,
Johnny Huard,
Christopher D. Harner
Publication year - 2019
Publication title -
clinical orthopaedics and related research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.178
H-Index - 204
eISSN - 1528-1132
pISSN - 0009-921X
DOI - 10.1097/corr.0000000000001080
Subject(s) - fibrin , mesenchymal stem cell , medicine , population , pathology , regeneration (biology) , wound healing , surgery , viability assay , andrology , in vitro , immunology , microbiology and biotechnology , biology , biochemistry , environmental health
Augmentation of soft-tissue repairs with an autologous fibrin clot has been used clinically for nearly four decades; however, fibrin clots tend to produce an abundance of scar tissue, which is known to inhibit soft-tissue regeneration. Mesenchymal stem cells (MSCs) embedded in fibrin clots before repair could reduce scar tissue deposition and facilitate soft-tissue regeneration. To our knowledge, no published studies have directly evaluated the viability or bioactivity of MSCs in fresh human fibrin clots over time. The purpose of this study was to evaluate the viability and bioactivity of human MSCs inside human fibrin clots over time in nutritive and non-nutritive culture media.